LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY

Autor: Zeijlemaker, W., Meijer, R., Kelder, A., Carbaat-Ham, J., Oussoren-brockhoff, Y., Snel, S., Veldhuizen, D., Scholten, W., Maertens, J., Breems, D., Pabst, T., Manz, M., Van der Velden, V., Slomp, J., Valk, P., Cloos, J., Lowenberg, B., Ossenkoppele, G., Schuurhuis, G. J.

Publikováno v: Haematologica, 102, 7-8. Ferrata Storti Foundation
Zeijlemaker, W, Meijer, R, Kelder, A, Carbaat-Ham, J, Oussoren-brockhoff, Y, Snel, S, Veldhuizen, D, Scholten, W, Maertens, J, Breems, D, Pabst, T, Manz, M, Van der Velden, V, Slomp, J, Valk, P, Cloos, J, Lowenberg, B, Ossenkoppele, G & Schuurhuis, G J 2017, ' LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY ', Haematologica, vol. 102, pp. 7-8 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f8515beed5f976fea07915d6a81557ac
https://research.vumc.nl/en/publications/08b5a729-d702-4e0f-8323-80bff0bf497f

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.